GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

Getting a drug from initial target discovery to U.S. regulatory approval takes between 10 and 15 years on average. Most of ...

ESTABLISHING a national precision medicine strategy, anchored by a clearly defined coordinating body tops the priority list ...

GPT-Rosalind steps in the earliest and most hypothesis-driven stages, where researchers juggle vast literature, specialised ...

Credit: VentureBeat made with OpenAI GPT-Image-1.5 The journey from a laboratory hypothesis to a pharmacy shelf is one of the ...

Efforts to improve cancer imaging technologies are crucial for diagnosing and treating the disease effectively. This transition from experimental to clinical use requires bridging the gap between ...

OpenAI is framing GPT-Rosalind as a tool to compress the timeline from scientific idea to clinical evidence. The company ...

OpenAI's GPT-Rosalind AI model aims to accelerate drug discovery timelines, partnering with Amgen, Moderna, and Thermo Fisher ...

While traditional kits confirmed infections, genomic sequencing was essential to investigate the outbreak's origin, ...

A skull fragment found in Burlington over a decade ago has been identified as belong to Arthur Weiss, who died at 87 in New ...

In the current global oncology landscape, solid tumors comprise over 70% of all cancer cases. They are responsible for the majority of cancer-related ...

Rosalind, a large language model built specifically for life sciences research, trained on 200 billion tokens from scientific ...